Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Core Insights - Esperion Therapeutics, Inc. (NASDAQ: ESPR) has experienced significant stock price appreciation, exceeding 30% this month after reaching a 52-week low of below $1 in April [1] Company Overview - Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) [1] Market Performance - The stock's recovery indicates a positive market sentiment and potential investor confidence in the company's future prospects [1]